MINNEAPOLIS - OneMedNet Corporation (NASDAQ:ONMD) announced today it has secured more than $3 million in new bookings for 2026 as of this announcement, surpassing the company’s total bookings for all of 2025, according to a press release statement.
The company expects to recognize substantially all of these bookings as revenue by the end of the third quarter of 2026. OneMedNet provides real-world data for life sciences organizations, focusing on regulatory submissions and research applications.The positive bookings news comes as the stock trades at $0.65, down nearly 16% over the past week, though investors who held shares over the past year have seen returns of 48%. The company, with a market cap of $35 million, reported revenue of $1.32 million over the last twelve months with growth of 148%.
The bookings were secured in just over five months of 2026. The company attributes the growth to new customer wins and expanded engagements with life sciences, medical device, and AI-focused clients using its iRWD Platform for foundation model development, cohort discovery, feasibility studies, and data delivery.
"Eclipsing our full prior-year bookings this early is powerful validation of our strategy," said Aaron Green, CEO and President.
OneMedNet’s platform is powered by Palantir Foundry and operates across a network of more than 2,300 healthcare partner sites. The company recently reported surpassing 90 million patient journeys and 270 million studies across its network.InvestingPro subscribers have access to 10 additional exclusive tips for ONMD, including insights on the company’s cash position and profitability metrics that provide crucial context for evaluating this growth trajectory.
The company expects continued momentum in the second half of 2026 as additional pipeline opportunities advance and existing customers expand their use of the platform for AI model training, regulatory studies, and longitudinal evidence generation.
OneMedNet provides de-identified medical imaging and electronic health records data to drugmakers, medical device companies, and AI developers. The company’s network spans rare diseases, oncology, and cardiology.
The information is based on a press release statement issued by the company.
In other recent news, OneMedNet Corporation reported a significant 329% increase in Real-World Data revenue, reaching $1.25 million in 2025, up from $292,000 in the previous year. The company’s fourth-quarter revenue hit $890,000. Additionally, OneMedNet reduced its total liabilities from $19.7 million to $5.1 million, improving its shareholder deficit from $(16.0) million to $(3.0) million. In another development, OneMedNet announced a collaboration with Inka Health, a subsidiary of Onco-Innovations Limited, to provide access to its iRWD platform for U.S. real-world oncology data. This partnership aims to support the development of Onco-Innovations’ PNKP Inhibitor Technology. Furthermore, OneMedNet received a notice from the Nasdaq Listing Qualifications Department for non-compliance with the minimum bid price requirement of $1.00. The company has until October 12, 2026, to regain compliance by maintaining a minimum bid price of $1.00 per share for at least ten consecutive business days. These recent developments reflect significant changes and collaborations for OneMedNet.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.